Alkermes (ALKS) Stock Price Target Raised to $53 by Mizuho
Published on 4/10/2026

AI Summary
Summarized by AI from the source belowMizuho increased its price target for Alkermes (ALKS) to $53, attributing the change to improved confidence in the company's drug pipeline. This revision reflects optimism regarding potential therapeutic advancements. The adjustment is significant for investors monitoring ALKS, as price targets can influence market sentiment and trading decisions. Increased confidence in drug development may correlate with higher stock valuations moving forward.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
Related News

Markets
Japan JP10Y Bond Yield Hits 2.945%, Weak Yen Impacts Bitcoin
Aug 23

Markets
Berkshire Hathaway (BRK.A) Has Nearly $400 Billion in Cash Reserves
Aug 23

Markets
Coca-Cola (KO) Outshines Celsius (CELH) as Cramer Recommends Shift
Aug 23

Markets
CAPE Ratio Hits 42.2, Highest Level Since Dot-Com Bubble
Aug 23